FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308773591> ?p ?o ?g. }

• W4308773591 endingPage "1372" @default.
• W4308773591 startingPage "1363" @default.
• W4308773591 abstract "Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the approach to patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study retrospectively analyzed patients treated with commercially available tisagenlecleucel at our hospital and evaluated its safety and effectiveness. Of the 21 patients evaluated, any grade and grade ≥3 cytokine release syndrome (CRS) occurred in 85.7% and 9.5% of the patients, respectively. A total of 66.7% received tocilizumab and 28.6% received glucocorticoids for the treatment of CRS. The complete response (CR) rate at 3 months was 61.9% (95% confidence interval [CI] 38.4-81.9). After a median follow-up of 6.3 months following CAR-T infusion, the progression-free survival (PFS) and overall survival rates at 6 months were 53.1% (95%CI 28.3-72.7) and 69.2% (95%CI 43.7-84.9), respectively. Severe cytopenia and hypogammaglobulinemia occurred frequently following CAR-T infusion. Eight patients (38.1%) had comorbidities that would have made them ineligible for leukapheresis in the JULIET trial. However, the presence of comorbidities at the time of leukapheresis had no significant effect on the rates of CR, PFS, and adverse events. Tisagenlecleucel for r/r DLBCL in the real-world setting showed high efficacy and manageable safety profile comparable with the pivotal trial." @default.
• W4308773591 created "2022-11-15" @default.
• W4308773591 creator A5000535152 @default.
• W4308773591 creator A5001104972 @default.
• W4308773591 creator A5002104620 @default.
• W4308773591 creator A5017341988 @default.
• W4308773591 creator A5018220902 @default.
• W4308773591 creator A5020948505 @default.
• W4308773591 creator A5020996692 @default.
• W4308773591 creator A5021699640 @default.
• W4308773591 creator A5027115692 @default.
• W4308773591 creator A5031112897 @default.
• W4308773591 creator A5032173181 @default.
• W4308773591 creator A5036639777 @default.
• W4308773591 creator A5037352597 @default.
• W4308773591 creator A5042854652 @default.
• W4308773591 creator A5047472576 @default.
• W4308773591 creator A5047555337 @default.
• W4308773591 creator A5048935550 @default.
• W4308773591 creator A5049066873 @default.
• W4308773591 creator A5049853926 @default.
• W4308773591 creator A5050522996 @default.
• W4308773591 creator A5052818876 @default.
• W4308773591 creator A5053415959 @default.
• W4308773591 creator A5064808239 @default.
• W4308773591 creator A5070416698 @default.
• W4308773591 creator A5071892296 @default.
• W4308773591 creator A5072533536 @default.
• W4308773591 creator A5076243524 @default.
• W4308773591 creator A5079282630 @default.
• W4308773591 creator A5080764443 @default.
• W4308773591 creator A5081560942 @default.
• W4308773591 creator A5087322537 @default.
• W4308773591 creator A5089071651 @default.
• W4308773591 creator A5091755258 @default.
• W4308773591 creator A5025646431 @default.
• W4308773591 creator A5076968063 @default.
• W4308773591 date "2022-01-01" @default.
• W4308773591 modified "2023-09-30" @default.
• W4308773591 title "[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience]." @default.
• W4308773591 doi "https://doi.org/10.11406/rinketsu.63.1363" @default.
• W4308773591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36351641" @default.
• W4308773591 hasPublicationYear "2022" @default.
• W4308773591 type Work @default.
• W4308773591 citedByCount "0" @default.
• W4308773591 crossrefType "journal-article" @default.
• W4308773591 hasAuthorship W4308773591A5000535152 @default.
• W4308773591 hasAuthorship W4308773591A5001104972 @default.
• W4308773591 hasAuthorship W4308773591A5002104620 @default.
• W4308773591 hasAuthorship W4308773591A5017341988 @default.
• W4308773591 hasAuthorship W4308773591A5018220902 @default.
• W4308773591 hasAuthorship W4308773591A5020948505 @default.
• W4308773591 hasAuthorship W4308773591A5020996692 @default.
• W4308773591 hasAuthorship W4308773591A5021699640 @default.
• W4308773591 hasAuthorship W4308773591A5025646431 @default.
• W4308773591 hasAuthorship W4308773591A5027115692 @default.
• W4308773591 hasAuthorship W4308773591A5031112897 @default.
• W4308773591 hasAuthorship W4308773591A5032173181 @default.
• W4308773591 hasAuthorship W4308773591A5036639777 @default.
• W4308773591 hasAuthorship W4308773591A5037352597 @default.
• W4308773591 hasAuthorship W4308773591A5042854652 @default.
• W4308773591 hasAuthorship W4308773591A5047472576 @default.
• W4308773591 hasAuthorship W4308773591A5047555337 @default.
• W4308773591 hasAuthorship W4308773591A5048935550 @default.
• W4308773591 hasAuthorship W4308773591A5049066873 @default.
• W4308773591 hasAuthorship W4308773591A5049853926 @default.
• W4308773591 hasAuthorship W4308773591A5050522996 @default.
• W4308773591 hasAuthorship W4308773591A5052818876 @default.
• W4308773591 hasAuthorship W4308773591A5053415959 @default.
• W4308773591 hasAuthorship W4308773591A5064808239 @default.
• W4308773591 hasAuthorship W4308773591A5070416698 @default.
• W4308773591 hasAuthorship W4308773591A5071892296 @default.
• W4308773591 hasAuthorship W4308773591A5072533536 @default.
• W4308773591 hasAuthorship W4308773591A5076243524 @default.
• W4308773591 hasAuthorship W4308773591A5076968063 @default.
• W4308773591 hasAuthorship W4308773591A5079282630 @default.
• W4308773591 hasAuthorship W4308773591A5080764443 @default.
• W4308773591 hasAuthorship W4308773591A5081560942 @default.
• W4308773591 hasAuthorship W4308773591A5087322537 @default.
• W4308773591 hasAuthorship W4308773591A5089071651 @default.
• W4308773591 hasAuthorship W4308773591A5091755258 @default.
• W4308773591 hasConcept C10205521 @default.
• W4308773591 hasConcept C121332964 @default.
• W4308773591 hasConcept C121608353 @default.
• W4308773591 hasConcept C126322002 @default.
• W4308773591 hasConcept C141071460 @default.
• W4308773591 hasConcept C142424586 @default.
• W4308773591 hasConcept C143998085 @default.
• W4308773591 hasConcept C159654299 @default.
• W4308773591 hasConcept C197934379 @default.
• W4308773591 hasConcept C203014093 @default.
• W4308773591 hasConcept C2777178219 @default.
• W4308773591 hasConcept C2777371436 @default.
• W4308773591 hasConcept C2777701055 @default.
• W4308773591 hasConcept C2777805810 @default.
• W4308773591 hasConcept C2778559949 @default.
• W4308773591 hasConcept C2779134260 @default.
• W4308773591 hasConcept C2779338263 @default.

• next